Business
Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n\n\nCelldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCelldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines\nPR Newswire\nBATON ROUGE, May 12, 2016\n\n\n\nBy Sara Bowman, Senior Writer, Online Media Group, Inc.\n\n\n\nBATON ROUGE, May 12, 2016 /PRNewswire/ - Developing cancer vaccines, a type of immunotherapy, has been notoriously difficult in the past, but not impossible.  Most notably, there are FDA approvals for three vaccines, although two, Gardasil and Cervarix, are preemptive in nature, fighting human papillomavirus (HPV) that often leads to cancer.  Gardasil, a product of Merck subsidiary Merck Sharp & Dohme Corp., is a vaccine that protects against four different types of HPV, namely in girls and young women (and males with anal cancer) in helping to prevent cervical, vaginal, vulvar and anal cancers. GlaxoSmithKline's Cervarix is indicated for girls and young women for the prevention of certain diseases cause by oncogenic HPV (types 16 and 18), including cervical cancer, adenocarcinoma and different grades of abnormal cell growth that can lead to cervical cancer (cervical intraepithelial neoplasia).  \n\nDendreon garnered FDA approval of Provenge (sipuleucel-T) in 2010 for metastatic castrate resistant (hormone refractory) prostate cancer patients who demonstrate minimal or no symptoms.  Although expectations were high, Provenge was a commercial failure due to its high cost, formulation difficulties, small patient population and narrow window of extending median survival by only 4.1 months.  In February 2015, Valeant Pharmaceuticals acquired all of assets of Dendreon during the company's Chapter 11 bankruptcy protection.\n\nBetter understanding of immunotherapies and ongoing clinical trials are providing valuable data for scientists to learn more about and advance new cancer vaccines.  As listed on ClinicalTrials.gov, there are more than 1,750 clinical trials related to cancer vaccines, including trials currently recruiting for melanoma, brea...